Abstract
The safety and effective dose of chemotherapy in treating non-Hodgkin lymphoma in elderly patients is yet to be established. In this study, we assessed the prognosis of diffuse large B-cell lymphoma (DLBCL) in elderly patients (≥75 years) treated with an optimal dose of R-CHOP. No significant differences were observed in progression-free survival between elderly patients and patients aged <74 years with DLBCL. Furthermore, no differences were observed between full-dose R-CHOP and 80% dose R-CHOP groups. Median relative dose intensity was 0.80 in elderly patients with DLBCL. Thus, our data suggested that 80% dose R-CHOP is tolerable and effective in these patients.
Keywords:
Chemotherapy; Diffuse large B-cell lymphoma; Elderly.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibodies, Monoclonal, Murine-Derived / adverse effects
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / adverse effects
-
Doxorubicin / therapeutic use
-
Female
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Male
-
Middle Aged
-
Multivariate Analysis
-
Prednisone / adverse effects
-
Prednisone / therapeutic use
-
Rituximab
-
Treatment Outcome
-
Vincristine / adverse effects
-
Vincristine / therapeutic use
-
Young Adult
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
R-CHOP protocol
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone